You just read:

Frost & Sullivan Publishes Quarterly Update on Oramed Pharmaceuticals Inc. - Sufficient funds for clinical development activity over the next 24 months; several clinical milestones are scheduled for 2018 and 2019; as Oramed's clinical progress meets our expectations, stock target price remains at NIS 53.2.

News provided by

Frost & Sullivan

07 Aug, 2018, 13:00 BST